-
The British Journal of Dermatology Aug 1986
Clinical Trial
Topics: Dermatitis, Contact; Drug Therapy, Combination; Humans; Mechlorethamine; PUVA Therapy; Psoriasis
PubMed: 3741804
DOI: 10.1111/j.1365-2133.1986.tb02115.x -
JAMA Nov 1972
Topics: Humans; Mechlorethamine; Mycosis Fungoides; Remission, Spontaneous; Skin Neoplasms; Solutions
PubMed: 4678061
DOI: 10.1001/jama.222.9.1172b -
Archives of Dermatology Mar 1973
Topics: Aged; Anaphylaxis; Diphenhydramine; Drug Hypersensitivity; Epinephrine; Female; Humans; Mechlorethamine; Mycosis Fungoides; Skin Tests; Solutions; Urticaria
PubMed: 4692132
DOI: No ID Found -
Journal of Pharmaceutical Sciences Jan 1984The structure-activity relationships of 2-dimethylaminoethanol and its analogues as protectors against mechlorethamine cytotoxicity and as inhibitors of choline uptake...
Protection of murine L1210 leukemia and bone marrow progenitor cells against mechlorethamine and inhibition of choline uptake as a structure-activity relationship of 2-dimethylaminoethanol and its analogues.
The structure-activity relationships of 2-dimethylaminoethanol and its analogues as protectors against mechlorethamine cytotoxicity and as inhibitors of choline uptake were evaluated. Of a series of inhibitors and protectors, 2-dimethylaminoethanol was the most potent inhibitor of choline uptake and the most potent protector of both hematopoietic progenitor cells and murine L1210 leukemia cells. Two analogues that exhibited both potent protection and inhibition were 1-dimethylamino-2-propanol and 2-ethylmethylaminoethanol. 2-Di-n-butylaminoethanol, while protecting against mechlorethamine cytotoxicity, was not an inhibitor of choline uptake. 2-n-Butylmethylaminoethanol, while an inhibitor of choline uptake, was not a protector against mechlorethamine cytotoxicity. Addition of 2-dimethylaminoethanol to mechlorethamine in a mole ratio of 1000:1 did not improve survival of tumor-bearing mice beyond that of mice treated with mechlorethamine alone.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Choline; Deanol; Ethanolamines; Female; Leukemia L1210; Male; Mechlorethamine; Mice; Mice, Inbred DBA; Stem Cells; Structure-Activity Relationship
PubMed: 6694079
DOI: 10.1002/jps.2600730109 -
Journal of Medicinal Chemistry Jan 1968
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Culture Techniques; Leukemia L1210; Mechlorethamine; Methods; Mice; Rats
PubMed: 5637191
DOI: 10.1021/jm00307a012 -
McGill Medical Journal Oct 1949
Topics: Mechlorethamine; Nitrogen Mustard Compounds
PubMed: 15402248
DOI: No ID Found -
The Journal of Pharmacology and... Nov 1966
Topics: Animals; Cerebral Ventricles; Chlorpromazine; Dogs; Emetics; Ergoloid Mesylates; Mechlorethamine; Perphenazine; Vomiting
PubMed: 4958820
DOI: No ID Found -
Journal of the American Academy of... Mar 1989Complete responses lasting from 4 to 14 years were documented in 65 of 331 (20%) patients with cutaneous T cell lymphoma treated with topical mechlorethamine (HN2)...
Complete responses lasting from 4 to 14 years were documented in 65 of 331 (20%) patients with cutaneous T cell lymphoma treated with topical mechlorethamine (HN2) between 1968 and 1982. Such long-lasting remissions occurred most often, but not invariably, in patients with patch or plaque phase mycosis fungoides without palpable lymphadenopathy (stage Ia or Ib). The likelihood of a continuous remission was enhanced by initiation of treatment before an unequivocal pathologic diagnosis. Despite the long-lasting responses in these patients, however, relapses have been documented in 11 (17%) of these patients, and all relapses occurred within 8 years of discontinuing maintenance topical chemotherapy. Thus, in our experience, a continuous remission lasting 8 or more years provides evidence that cutaneous T cell lymphoma can be eradicated by aggressive topical chemotherapy. This circumstance was observed in 35 patients, representing a cure rate of at least 11% overall. In addition, when compared with the general population of the United States, patients who received topical HN2 were at an 8.6-fold and a 1.8-fold increased risk for the development of squamous cell carcinoma and enhanced for Hodgkin's disease and colon cancer but not for systemic cancers known to be induced by systemic administration of alkylating drugs. These results compare favorably with experiences with topical HN2 chemotherapy at other centers but raise questions about the risks associated with long-term administration for maintenance of remissions.
Topics: Administration, Cutaneous; Age Factors; Aged; Female; Follow-Up Studies; Humans; Lymphoma; Male; Mechlorethamine; Middle Aged; Mycosis Fungoides; Neoplasms; Recurrence; Remission Induction; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Wilms Tumor
PubMed: 2537348
DOI: 10.1016/s0190-9622(89)70051-7 -
Nature Nov 1979
Topics: Animals; Bone Marrow; Chemical Warfare; Guinea Pigs; History, 20th Century; Lymphocytes; Mechlorethamine
PubMed: 386138
DOI: 10.1038/282128d0 -
Acta Dermato-venereologica Jun 2022Chlormethine is a bifunctional cytotoxic alkylating agent that binds to DNA, resulting in cell death (apoptosis). Chlormethine (also known as mechlorethamine) gel (CL...
Chlormethine is a bifunctional cytotoxic alkylating agent that binds to DNA, resulting in cell death (apoptosis). Chlormethine (also known as mechlorethamine) gel (CL gel) was approved in the European Union in 2017 and was first used in 2019. The aim of the study is to examine evidence regarding the efficacy and safety of chlormethine gel in everyday clinical experience from a cutaneous lymphoma centre. Twenty-three patients with stage IA-IIB mycosis fungoides received chlormethine gel between September 2020 and May 2021. All patients started by applying the gel daily and were monitored every month. At 1, 3, 6 and 9 months, 0%, 43.47%, 56.52% and 65.22% of patients, respectively, achieved an overall response. Five out of 23 patients (21.73%) achieved near complete response at a mean time of 6 months. Chlormethine gel was given as monotherapy in 12 patients (52.17%), and in addition to systemic treatments (methotrexate and peginterferon alpha-2a) in 11 patients (47.82%). Adverse events (AE) were recorded in 43.47% of patients, but only 3 discontinued treatment, due to dermatitis. Scale down of the treatment to application 3-times per week led to better patient compliance. This study shows that chlormethine gel is effective and safe in patients with mycosis fungoides with different types of skin lesions.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Humans; Mechlorethamine; Mycosis Fungoides; Skin Diseases; Skin Neoplasms
PubMed: 35199177
DOI: 10.2340/actadv.v102.1095